The Realities and Associated Factors of Palliative Chemotherapy Near the End of Life in the Patients Enrolled in Palliative Care Unit
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: It is important to know and decide when to end regimen for the quality of life of the patients. However, there is currently no clear agreement on when to terminate palliative chemotherapy. We investigated the duration between the last chemotherapy and death, and associated factors affecting patients receiving palliative care after the last chemotherapy. Methods: We studied 242 patients who were put into palliative care ward after receiving chemotherapy and died during hospitalization from 2008 to 2009. Electronic medical records were used to gather information on demographic characteristics,types of primary cancer, and palliative chemotherapy. Then we analyzed the relationship between the clinical characteristics of patients and interval between last chemotherapy and death. Results: The average survival time of patients after referral to palliative care was 17.5 days; survival time after discontinuation of chemotherapy was 103 days. Also, 104 (43.0%) patients died within 3 months and 14 (5.8%) patients died within 1 month of persistent palliative chemotherapy. Chemotherapy on patients within 3 months from their death was not associated with the social characteristics of the population. Conclusion: The patients who were referred to palliative care were found to have continued to receive chemotherapy within 3months before death. However, only a small number of patients received chemotherapy within 1 month before death, which confirms that futile chemotherapy that extends to the end of life was less frequent. Doctors should be able to recognize the implications of excessive and aggressive use of chemotherapy and should actively communicate with patients about therapeutic choices.
Abstract
Background: It is important to know and decide when to end regimen for the quality of life of the patients. However, there is currently no clear agreement on when to terminate palliative chemotherapy. We investigated the duration between the last chemotherapy and death, and associated factors affecting patients receiving palliative care after the last chemotherapy. Methods: We studied 242 patients who were put into palliative care ward after receiving chemotherapy and died during hospitalization from 2008 to 2009. Electronic medical records were used to gather information on demographic characteristics,types of primary cancer, and palliative chemotherapy. Then we analyzed the relationship between the clinical characteristics of patients and interval between last chemotherapy and death. Results: The average survival time of patients after referral to palliative care was 17.5 days; survival time after discontinuation of chemotherapy was 103 days. Also, 104 (43.0%) patients died within 3 months and 14 (5.8%) patients died within 1 month of persistent palliative chemotherapy. Chemotherapy on patients within 3 months from their death was not associated with the social characteristics of the population. Conclusion: The patients who were referred to palliative care were found to have continued to receive chemotherapy within 3months before death. However, only a small number of patients received chemotherapy within 1 month before death, which confirms that futile chemotherapy that extends to the end of life was less frequent. Doctors should be able to recognize the implications of excessive and aggressive use of chemotherapy and should actively communicate with patients about therapeutic choices.
참고문헌 (15)
- (2011)[URL]
- Earle CC, "Trends in the aggressiveness of cancer care near the end of life", J Clin Oncol, 22, pp.315~321 (2004)
- Borras JM, "Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial", BMJ, 322, pp.826~ (2001)
- Harrington SE, "The role of chemotherapy at the end of life: "when is enough, enough?"", JAMA, 299, pp.2667~2678 (2008)
- Yun YH, "Chemotherapy use and associated factors among cancer patients near the end of life", ONCOLOGY, 72(3-4), pp.164~171, KARGER
- Keam B, "Aggressiveness of cancer-care near the end-of-life in Korea", Jpn J Clin Oncol, 38, pp.381~386 (2008)
- Earle CC, "Aggressiveness of cancer care near the end of life: is it a quality-of-care issue?", J Clin Oncol, 26, pp.3860~3866 (2008)
- Kao S, "Use of chemotherapy at end of life in oncology patients", Ann Oncol, 20, pp.1555~1559 (2009)
- Murillo JR Jr, "Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer", Oncologist, 11, pp.1095~1099 (2006)
- Hashimoto K, "Factors that affect the duration of the interval between the completion of palliative chemotherapy and death", Oncologist, 14, pp.752~759 (2009)
- Earle CC, "Trends in the aggressiveness of cancer care near the end of life", J Clin Oncol, 22, pp.315~321 (2004)
- Koedoot CG, "Palliative chemotherapy or best supportive care? A prospective study explaining patients' treatment preference and choice", Br J Cancer, 89, pp.2219~2226 (2003)
- 염창환, "말기 암 환자의 호스피스 완화의료에 대한 의사들의 태도", 한국호스피스완화의료학회지, 9(2), pp.93~100 (2006), 한국호스피스완화의료학회
- von Gunten CF, "Discussing hospice care", J Clin Oncol, 21(9), pp.31s~36s (2003)
- Koedoot CG, "The content and amount of information given by medical oncologists when telling patients with advanced cancer what their treatment options are: palliative chemotherapy and watchful-waiting", Eur J Cancer, 40, pp.225~235 (2004)